HUA MEDICINE-B (02552) surged over 14%, reaching an intraday high of HK$4.7, marking its highest level since February 2023. As of press time, the stock was up 14% at HK$4.56 with trading volume of HK$182 million.

On the news front, HUA MEDICINE-B recently announced its interim results for 2025. During the reporting period, Huatangning® sales volume reached 1.764 million boxes, representing a 108% year-on-year increase, while net sales totaled 217.4 million yuan, up 112% year-on-year.

Notably, following the termination of the exclusive promotion service agreement with Bayer, the company recognized one-time deferred revenue of 1.2435 billion yuan, achieving a profit of 1.1839 billion yuan in the first half - marking its first profitable performance period and demonstrating the significant success of its commercial transformation. Meanwhile, expanded production scale and improved operational efficiency drove gross margin to 54.2%, an increase of 7.7 percentage points year-on-year, showing a clear positive trend in profitability.

Additionally, HUA MEDICINE-B is actively expanding its overseas business and accelerating its global expansion. The company has submitted a registration application to Hong Kong for dorzagliatin 75mg (trade name: Hualingpian®, MYHOMSISTM), which will accelerate its expansion in the Greater China region and Southeast Asian markets.

Furthermore, based on the preliminary success of the Phase I single ascending dose study in the United States, the company plans to initiate a multiple ascending dose Phase I study by the end of 2025 or early 2026, continuing to advance the development of its second-generation GKA in global markets.